Related Experiment Video
Updated: Jul 3, 2026
09:45
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
6.7K
MET and Small-Cell Lung Cancer.
Francesco Gelsomino1, Giulio Rossi2, Marcello Tiseo3
1Medical Oncology Unit 1, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milano, Italy. francesco.gelsomino@istitutotumori.mi.it.
Cancers
|October 15, 2014
Summary
Small-cell lung cancer (SCLC) is aggressive and often diagnosed late. Targeting the MET/HGF pathway offers a promising strategy to combat SCLC invasiveness and progression, improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Small-cell lung cancer (SCLC) is a highly aggressive malignancy with poor prognosis.
- Most SCLC patients are diagnosed at advanced stages, and while initially responsive to chemo-radiation, tumors invariably relapse.
- Current treatment options for relapsed SCLC are limited.
Purpose of the Study:
- To review recent molecular profiling data in SCLC.
- To highlight the aberrant MET/HGF signaling pathway in SCLC progression and invasiveness.
- To discuss c-MET gene alterations as potential therapeutic targets in SCLC.
Main Methods:
- Literature review of recent studies on SCLC molecular profiling.
- Analysis of data concerning the MET/HGF signaling axis in SCLC.
- Examination of c-MET gene alterations and their therapeutic implications.
Main Results:
- Molecular profiling reveals aberrant signaling pathways in SCLC.
- The MET/HGF axis is frequently implicated in SCLC invasiveness and progression.
- Specific alterations in the c-MET gene present potential therapeutic vulnerabilities.
Conclusions:
- Understanding SCLC molecular biology is key to identifying new therapeutic targets.
- Targeting the MET/HGF pathway holds promise for SCLC treatment.
- c-MET alterations represent a significant area for novel SCLC drug development.
